Lansoprazole Teva

Lansoprazole, the active ingredient in Lansoprazole Teva, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid secretion and is prescribed for conditions such as gastro‑oesophageal reflux disease, erosive esophagitis, peptic ulcer disease and as part of Helicobacter pylori eradication regimens in adult patients.

GNH USA supplies Lansoprazole Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company emphasizes quality assurance, regulatory compliance and reliable logistics to meet international standards.

Lansoprazole is a proton pump inhibitor used to manage acid‑related disorders by decreasing gastric acid production. - Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and regurgitation by maintaining a higher gastric pH. - Erosive esophagitis: promotes healing of inflamed esophageal tissue caused by acid exposure. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence in the stomach and duodenum. - Helicobacter pylori eradication (in combination therapy): enhances the effectiveness of antibiotic regimens by creating a less acidic environment.

Lansoprazole may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild, transient pain that may occur early in treatment and usually resolves without medication. - Diarrhea: loose, watery stools that are generally self‑limiting but can cause dehydration if persistent. - Abdominal pain: discomfort or cramping in the stomach region, often mild and improves with continued use. - Nausea: a sensation of queasiness that may lessen after several days of therapy.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis characterized by profuse watery diarrhea, abdominal pain and fever, requiring prompt medical attention. - Interstitial nephritis: inflammation of the kidney interstitium that can lead to reduced renal function and may necessitate discontinuation of therapy.

Before prescribing Lansoprazole, clinicians should consider several precautionary measures to ensure safe use. - Assess renal function: dose adjustment may be required in patients with severe renal impairment. - Evaluate for osteoporosis risk: long‑term use can affect calcium absorption, increasing fracture risk in susceptible individuals. - Monitor for infections: reduced stomach acidity may predispose to gastrointestinal infections such as C. difficile. - Use with caution in hepatic impairment: metabolism occurs in the liver, and severe dysfunction may increase exposure. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Lansoprazole can alter the plasma concentrations of several co‑administered medicines, necessitating careful review of the patient’s medication list.

Major Interactions (Avoid): - Antifungal agents (e.g., ketoconazole, itraconazole): reduced absorption leading to therapeutic failure. - HIV protease inhibitors (e.g., atazanavir): decreased plasma levels compromising antiviral efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring more frequent coagulation monitoring. - Digoxin: modest rise in serum concentration, may need dose adjustment. - Clopidogrel: reduced activation of the antiplatelet prodrug, potentially diminishing antithrombotic effect.